Most Read Articles
Pearl Toh, 18 Feb 2016
Treatment with eluxadoline, a new oral medication, relieved two major symptoms of irritable bowel syndrome with diarrhoea (IBS-D) — abdominal pain and diarrhoea, according to a study based on two phase III randomized controlled trials. [N Engl J Med 2016;374:242-253]
Su Ping Chuah, 01 Aug 2014

The Lancet has launched a special series issue that highlights the global HIV epidemic among sex workers, a key but overlooked population for HIV prevention. The series – launched at the 20th International AIDS conference in Melbourne – consists of seven papers that aim to investigate the complex health issues faced by sex workers worldwide, and calls for the decriminalization of sex work, in the global effort to tackle the HIV/AIDS epidemic. [Available at www.thelancet.com/series/HIV-and-sex-workers. Accessed on 23 July 2014]

Tristan Manalac, 2 days ago
Taking oral antibiotics appears to increase the risk of nephrolithiasis, according to a recent study. Moreover, the risk seems to be compounded for individuals with recent antibiotic exposure and those who were exposed at a younger age.
Roshini Claire Anthony, 20 Mar 2018

Individuals with type 2 diabetes (T2D) who initiate therapy with sodium glucose cotransporter-2 (SGLT-2) inhibitors have lower risks of all-cause death and cardiovascular (CV) outcomes, specifically myocardial infarction (MI) and stroke, compared with those who initiate other glucose-lowering therapies, according to results from the CVD-REAL* 2 study.

Combination therapy improves PFS in NSCLC

Audrey Abella
10 May 2018

Combining the monoclonal antibody atezolizumab with a carboplatin-paclitaxel chemotherapy regimen and the biologic antiangiogenic agent bevacizumab led to a significant progression-free survival (PFS) benefit in chemotherapy-naïve patients with non-squamous metastatic non-small-cell lung cancer (mNSCLC), according to the IMpower150* trial presented at ELCC 2018.

A total of 1,202 patients received chemotherapy (6AUC** carboplatin and paclitaxel 200 mg/m2) either with atezolizumab 1,200 mg (group 1), atezolizumab and bevacizumab 15 mg/kg (group 2), or bevacizumab (group 3). The ITT*** wild-type (WT) sample included EGFR- or ALK-negative participants from groups 2 and 3 (median age 63 years, n=356 and 336, respectively), while the T-effector (TEFF) WT population included those with expression of a tumour TEFF gene signature (n=155 and 129, respectively). [ELCC 2018, abstract 134PD]

The study drugs were administered intravenously every three weeks for four or six cycles depending on investigator’s discretion. Maintenance regimen included atezolizumab or bevacizumab for groups 1 and 3, respectively, and both for group 2.

Median PFS was superior in group 2 vs group 3 in both the ITT-WT and the TEFF-WT populations (8.3 vs 6.8 months, hazard ratio [HR], 0.62, 95 percent confidence interval [CI], 0.52–0.74; p<0.0001 and 11.3 vs 6.8 months, HR, 0.51, 95 percent CI, 0.38–0.68; p<0.0001, respectively).

PFS benefit remained consistent regardless of PD-L1 immunohistochemistry status, including PD-L1-negative patients (TC0/IC0#, HR, 0.77, 95 percent CI, 0.61–0.99).

Higher objective response rates were observed in group 2 vs group 3 (64.0 percent vs 48.0 percent and 69.0 percent vs 54.0 percent in the ITT-WT and TEFF-WT populations, respectively).

Safety profile was comparable between groups 2 and 3 (25 percent vs 19 percent treatment-related serious adverse events, respectively).

The clinically relevant survival benefit and lack of toxicity issues highlight the potential of targeting multiple pathways, favouring the addition of atezolizumab to bevacizumab and chemotherapy for first-line mNSCLC treatment, noted the researchers.

Atezolizumab restores anticancer immunity through PD-L1 inhibition, bevacizumab inhibits vascular endothelial growth factor-related immunosuppression and promotes T-cell tumour infiltration, while chemotherapy may induce immune responses, they added.

The association between groups 1 and 3 has not been established due to prespecified statistical testing hierarchy, noted the researchers.

 

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Pharmacist - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Pearl Toh, 18 Feb 2016
Treatment with eluxadoline, a new oral medication, relieved two major symptoms of irritable bowel syndrome with diarrhoea (IBS-D) — abdominal pain and diarrhoea, according to a study based on two phase III randomized controlled trials. [N Engl J Med 2016;374:242-253]
Su Ping Chuah, 01 Aug 2014

The Lancet has launched a special series issue that highlights the global HIV epidemic among sex workers, a key but overlooked population for HIV prevention. The series – launched at the 20th International AIDS conference in Melbourne – consists of seven papers that aim to investigate the complex health issues faced by sex workers worldwide, and calls for the decriminalization of sex work, in the global effort to tackle the HIV/AIDS epidemic. [Available at www.thelancet.com/series/HIV-and-sex-workers. Accessed on 23 July 2014]

Tristan Manalac, 2 days ago
Taking oral antibiotics appears to increase the risk of nephrolithiasis, according to a recent study. Moreover, the risk seems to be compounded for individuals with recent antibiotic exposure and those who were exposed at a younger age.
Roshini Claire Anthony, 20 Mar 2018

Individuals with type 2 diabetes (T2D) who initiate therapy with sodium glucose cotransporter-2 (SGLT-2) inhibitors have lower risks of all-cause death and cardiovascular (CV) outcomes, specifically myocardial infarction (MI) and stroke, compared with those who initiate other glucose-lowering therapies, according to results from the CVD-REAL* 2 study.